Type 2 Diabetes Mellitus: A Review of Multi-Target Drugs

2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

(2019) John B. Buse et al.   DIABETES CARE

IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045

(2018) N.H. Cho et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

A novel GLP-1/xenin hybrid peptide improves glucose homeostasis, circulating lipids and restores GIP sensitivity in high fat fed mice

(2018) Annie Hasib et al.   PEPTIDES

Precision medicine in diabetes prevention, classification and management

(2018) Fangying Xie et al.   Journal of Diabetes Investigation

Chimeric peptide EP45 as a dual agonist at GLP-1 and NPY2R receptors

(2018) Oleg G. Chepurny et al.   Scientific Reports

Precision medicine in the management of type 2 diabetes

(2018) Anna L Gloyn et al.   Lancet Diabetes & Endocrinology

An investigation on 4-thiazolidinone derivatives as dual inhibitors of aldose reductase and protein tyrosine phosphatase 1B, in the search for potential agents for the treatment of type 2 diabetes mellitus and its complications

(2018) Rosanna Maccari et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Gut microbiome and type 2 diabetes: where we are and where to go?

(2018) Sapna Sharma et al.   JOURNAL OF NUTRITIONAL BIOCHEMISTRY

Physiological role of adiponectin in different tissues: a review

(2018) S. Esmaili et al.   ARCHIVES OF PHYSIOLOGY AND BIOCHEMISTRY

LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept

(2018) Tamer Coskun et al.   Molecular Metabolism

Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel

(2017) Brian A. Ference et al.   EUROPEAN HEART JOURNAL

Combination SGLT2 inhibitor and GLP-1 receptor agonist therapy: a complementary approach to the treatment of type 2 diabetes

(2017) Robert S. Busch et al.   POSTGRADUATE MEDICINE

An Overview of Herbal Products and Secondary Metabolites Used for Management of Type Two Diabetes

(2017) Ajda Ota et al.   Frontiers in Pharmacology

Genes, Genetics, and Environment in Type 2 Diabetes: Implication in Personalized Medicine

(2016) Nabodita Kaul et al.   DNA AND CELL BIOLOGY

The effect of bariatric surgery on gastrointestinal and pancreatic peptide hormones

(2016) Claire L Meek et al.   PEPTIDES

Deciphering Metabolic Messages From the Gut Drives Therapeutic Innovation: The 2014 Banting Lecture

(2015) Daniel J. Drucker   DIABETES

SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials

(2015) Silvio E Inzucchi et al.   Diabetes & Vascular Disease Research

Pathophysiology of diabetic dyslipidaemia: where are we?

(2015) Bruno Vergès   DIABETOLOGIA

The role of fatty acids in insulin resistance

(2015) Barry Sears et al.   Lipids in Health and Disease

Glucagon and Type 2 Diabetes: the Return of the Alpha Cell

(2014) Asger Lund et al.   Current Diabetes Reports

Coinfusion of Low-Dose GLP-1 and Glucagon in Man Results in a Reduction in Food Intake

(2014) Jaimini Cegla et al.   DIABETES

Comparison of stability, cellular, glucose-lowering and appetite supressing effects of oxyntomodulin analogues modified at the N-terminus

(2014) Aisling M. Lynch et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Risk Factors Contributing to Type 2 Diabetes and Recent Advances in the Treatment and Prevention

(2014) Yanling Wu et al.   International Journal of Medical Sciences

Genetics of Type 2 Diabetes: Insights into the Pathogenesis and Its Clinical Application

(2014) Xue Sun et al.   Biomed Research International

Use of systems pharmacology modeling to elucidate the operating characteristics of SGLT1 and SGLT2 in renal glucose reabsorption in humans

(2014) Yasong Lu et al.   Frontiers in Pharmacology

Importance of Beta Cell Function for the Treatment of Type 2 Diabetes

(2014) Yoshifumi Saisho   Journal of Clinical Medicine

Narrative Review: The Role of Leptin in Human Physiology: Emerging Clinical Applications

(2013) Theodore Kelesidis   ANNALS OF INTERNAL MEDICINE

Effects of chronic exposure of clonal β-cells to elevated glucose and free fatty acids on incretin receptor gene expression and secretory responses to GIP and GLP-1

(2013) V. Pathak et al.   DIABETES OBESITY & METABOLISM

A DPP-IV-resistant triple-acting agonist of GIP, GLP-1 and glucagon receptors with potent glucose-lowering and insulinotropic actions in high-fat-fed mice

(2013) V. K. Bhat et al.   DIABETOLOGIA

Glucagon and GLP-1 inhibit food intake and increase c-fos expression in similar appetite regulating centres in the brainstem and amygdala

(2013) J A Parker et al.   INTERNATIONAL JOURNAL OF OBESITY

Emerging combinatorial hormone therapies for the treatment of obesity and T2DM

(2013) Sharon A. Sadry et al.   Nature Reviews Endocrinology

Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans

(2013) B. Finan et al.   Science Translational Medicine

Optimization of co-agonism at GLP-1 and glucagon receptors to safely maximize weight reduction in DIO-rodents

(2012) Jonathan W. Day et al.   BIOPOLYMERS

LX4211, a Dual SGLT1/SGLT2 Inhibitor, Improved Glycemic Control in Patients With Type 2 Diabetes in a Randomized, Placebo-Controlled Trial

(2012) B Zambrowicz et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Why Do SGLT2 Inhibitors Inhibit Only 30-50% of Renal Glucose Reabsorption in Humans?

(2012) J. Liu et al.   DIABETES

Unraveling oxyntomodulin, GLP1's enigmatic brother

(2012) Alessandro Pocai   JOURNAL OF ENDOCRINOLOGY

GLP-1 receptor agonists and HBA1ctarget of

(2011) K. Esposito et al.   CURRENT MEDICAL RESEARCH AND OPINION

α-Glucosidase Inhibition Properties of Cucurbitane-Type Triterpene Glycosides from the Fruits of Momordica charantia

(2010) Nguyen Xuan Nhiem et al.   CHEMICAL & PHARMACEUTICAL BULLETIN

Genomics, Type 2 Diabetes, and Obesity

(2010) Mark I. McCarthy   NEW ENGLAND JOURNAL OF MEDICINE

The emerging genetics of type 2 diabetes

(2010) Amélie Bonnefond et al.   TRENDS IN MOLECULAR MEDICINE

On the role of glucose-dependent insulintropic polypeptide in postprandial metabolism in humans

(2009) Meena Asmar et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

Glucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in Mice

(2009) A. Pocai et al.   DIABETES

Korean red ginseng (Panax ginseng) improves insulin sensitivity and attenuates the development of diabetes in Otsuka Long-Evans Tokushima fatty rats

(2009) Hyun Joo Lee et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

A new glucagon and GLP-1 co-agonist eliminates obesity in rodents

(2009) Jonathan W Day et al.   Nature Chemical Biology

Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes

(2008) P. V. Højberg et al.   DIABETOLOGIA

Low serum adiponectin level as a predictor of impaired glucose regulation and type 2 diabetes mellitus in a middle-aged Finnish population

(2008) Kirsti Jalovaara et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Antiobesity effects of wild ginseng (Panax ginsengC.A. Meyer) mediated by PPAR-γ, GLUT4 and LPL in ob/ob mice

(2008) Mohammad Lalmoddin Mollah et al.   PHYTOTHERAPY RESEARCH